Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4,778 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Trial Protocol of Biweekly TAS-102 and Bevacizumab as Third-Line Chemotherapy for Advanced/Recurrent Colorectal Cancer: A Phase II Multicenter Clinical Trial (The TAS-CC4 Study).
Yoshida Y, Yamada T, Matsuoka H, Sonoda H, Fukazawa A, Yoshida H, Ishida H, Hirata K, Hasegawa S, Sakamoto K, Otsuka T, Koda K. Yoshida Y, et al. Among authors: sakamoto k. J Anus Rectum Colon. 2019 Jul 30;3(3):136-141. doi: 10.23922/jarc.2018-043. eCollection 2019. J Anus Rectum Colon. 2019. PMID: 31583329 Free PMC article.
Efficacy and safety of neoadjuvant chemotherapy with oxaliplatin, 5-fluorouracil, and levofolinate for T3 or T4 stage II/III rectal cancer: the FACT trial.
Koike J, Funahashi K, Yoshimatsu K, Yokomizo H, Kan H, Yamada T, Ishida H, Ishibashi K, Saida Y, Enomoto T, Katsumata K, Hisada M, Hasegawa H, Koda K, Ochiai T, Sakamoto K, Shiokawa H, Ogawa S, Itabashi M, Kameoka S. Koike J, et al. Among authors: sakamoto k. Cancer Chemother Pharmacol. 2017 Mar;79(3):519-525. doi: 10.1007/s00280-017-3243-7. Epub 2017 Feb 1. Cancer Chemother Pharmacol. 2017. PMID: 28150022 Clinical Trial.
Characteristics and prognosis of Japanese colorectal cancer patients: The BioBank Japan Project.
Tamakoshi A, Nakamura K, Ukawa S, Okada E, Hirata M, Nagai A, Matsuda K, Kamatani Y, Muto K, Kiyohara Y, Yamagata Z, Ninomiya T, Kubo M, Nakamura Y; BioBank Japan Cooperative Hospital Group. Tamakoshi A, et al. J Epidemiol. 2017 Mar;27(3S):S36-S42. doi: 10.1016/j.je.2016.12.004. Epub 2017 Feb 15. J Epidemiol. 2017. PMID: 28214186 Free PMC article.
Combination of TAS-102 and bevacizumab as third-line treatment for metastatic colorectal cancer: TAS-CC3 study.
Yoshida Y, Yamada T, Kamiyama H, Kosugi C, Ishibashi K, Yoshida H, Ishida H, Yamaguchi S, Kuramochi H, Fukazawa A, Sonoda H, Yoshimatsu K, Matsuda A, Hasegawa S, Sakamoto K, Otsuka T, Koda K; TAS CC3 Study Group.. Yoshida Y, et al. Among authors: sakamoto k. Int J Clin Oncol. 2021 Jan;26(1):111-117. doi: 10.1007/s10147-020-01794-8. Epub 2020 Oct 21. Int J Clin Oncol. 2021. PMID: 33083913 Clinical Trial.
Risk of emergency surgery for complicated appendicitis: Japanese nationwide study.
Yamada T, Endo H, Hasegawa H, Kimura T, Kakeji Y, Koda K, Ishida H, Sakamoto K, Hirata K, Yamamoto H, Miyata H, Matsuda A, Yoshida H, Kitagawa Y. Yamada T, et al. Among authors: sakamoto k. Ann Gastroenterol Surg. 2020 Nov 9;5(2):236-242. doi: 10.1002/ags3.12408. eCollection 2021 Mar. Ann Gastroenterol Surg. 2020. PMID: 33860144 Free PMC article.
The Pre-treatment Lymphocyte-to-Monocyte Ratio Predicts Efficacy in Metastatic Colorectal Cancer Treated With TAS-102 and Bevacizumab.
Kuramochi H, Yamada T, Yoshida Y, Matsuda A, Kamiyama H, Kosugi C, Ishibashi K, Fukazawa A, Ihara K, Sonoda H, Yoshimatsu K, Yoshida H, Hasegawa S, Sakamoto K, Ishida H, Koda K; TAS CC3 Study Group. Kuramochi H, et al. Among authors: sakamoto k. Anticancer Res. 2021 Jun;41(6):3131-3137. doi: 10.21873/anticanres.15098. Anticancer Res. 2021. PMID: 34083307
A Trial Protocol of Precision Medicine for Patients with RAS Wild Metastatic Colorectal Cancer Using Liquid Biopsy (RAS-liquid Study): A Prospective, Multicenter Observational Study.
Matsuda A, Yamada T, Takahashi T, Hirata K, Nagasaka T, Ishimaru K, Sakamoto K, Koda K, Ishikawa T, Ishida H, Matsuda K, Kuramochi H, Yoshida Y, Sonoda H, Yoshida H. Matsuda A, et al. Among authors: sakamoto k. J Anus Rectum Colon. 2022 Jan 28;6(1):52-57. doi: 10.23922/jarc.2021-042. eCollection 2022. J Anus Rectum Colon. 2022. PMID: 35128137 Free PMC article.
Characteristics of anal canal cancer in Japan.
Yamada K, Saiki Y, Komori K, Shiomi A, Ueno M, Ito M, Hida K, Yamamoto S, Shiozawa M, Ishihara S, Kanemitsu Y, Ueno H, Kinjo T, Maeda K, Kawamura J, Fujita F, Takahashi K, Mizushima T, Shimada Y, Sasaki S, Sunami E, Ishida F, Hirata K, Ohnuma S, Funahashi K, Watanabe J, Kinugasa Y, Yamaguchi S, Hashiguchi Y, Ikeda M, Sudo T, Komatsu Y, Koda K, Sakamoto K, Okajima M, Ishida H, Hisamatsu Y, Masuda T, Mori S, Minami K, Hasegawa S, Endo S, Iwashita A, Hamada M, Ajioka Y, Usuku K, Ikeda T, Sugihara K. Yamada K, et al. Among authors: sakamoto k. Cancer Med. 2022 Jul;11(14):2735-2743. doi: 10.1002/cam4.4631. Epub 2022 Mar 10. Cancer Med. 2022. PMID: 35274487 Free PMC article.
Efficacy and safety of regorafenib dose-escalation therapy for Japanese patients with refractory metastatic colorectal cancer (RECC study).
Ishiyama S, Yamada T, Nakamura M, Enomoto M, Sugimoto K, Yokomizo H, Kosugi C, Ohta R, Ishimaru K, Sonoda H, Ishibashi K, Kuramochi H, Yoshida Y, Ichikawa D, Hirata K, Yoshida H, Hashiguchi Y, Ishida H, Koda K, Katsumata K, Sakamoto K. Ishiyama S, et al. Among authors: sakamoto k. Int J Clin Oncol. 2022 Aug;27(8):1300-1308. doi: 10.1007/s10147-022-02179-9. Epub 2022 May 30. Int J Clin Oncol. 2022. PMID: 35635652 Clinical Trial.
4,778 results